Last reviewed · How we verify
IN10018（Ifebemtinib）
At a glance
| Generic name | IN10018（Ifebemtinib） |
|---|---|
| Also known as | BI 853520 |
| Sponsor | InxMed (Shanghai) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IN10018（Ifebemtinib） CI brief — competitive landscape report
- IN10018（Ifebemtinib） updates RSS · CI watch RSS
- InxMed (Shanghai) Co., Ltd. portfolio CI